Angelos D. Gritzapis
Cancer Immunology and Immunotherapy Center
Saint Savas Cancer Hospital
171 Alexandras Avenue
11522 Athens
Greece
Name/email consistency: high
- Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Gritzapis, A.D., Voutsas, I.F., Lekka, E., Papamichail, M., Baxevanis, C.N. Cancer Res. (2010)
- Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. Gritzapis, A.D., Voutsas, I.F., Lekka, E., Tsavaris, N., Missitzis, I., Sotiropoulou, P., Perez, S., Papamichail, M., Baxevanis, C.N. J. Immunol. (2008)
- Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Gritzapis, A.D., Mahaira, L.G., Perez, S.A., Cacoullos, N.T., Papamichail, M., Baxevanis, C.N. Cancer Res. (2006)